1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
i-SENS, Inc.

i-SENS, Inc.

099190.KQ
i-SENS, Inc.KR flagKOSDAQ
16,800.00
KRW
-210.00
- -
463.44BMarket Cap
i-SENS, Inc.
099190.KQ
(KOSDAQ)

Recent

price

16,800.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,759.98
3,090.73
3,513.83
3,729.59
4,827.75
5,717.58
6,313.59
6,981.63
7,491.44
8,566.89
4,824.76
9,649.67
10,548.16
11,456.43
11,338.06
Revenue per Share
362.67
695.33
531.67
538.5
640
573
825.5
861.5
987
936.04
294
135
-65
-187
-209.04
Basic EPS, GAAP
-450.02
-474.2
351.77
322.47
114.22
-66.82
328.69
1,115.44
978.64
-1,139
-302.68
-1,077.48
267.33
-302.83
-509.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
49.98
50.12
74.99
99.99
125
74.3
174.93
99.67
100.38
- -
Dividend per Share
1,592.31
2,101.19
2,569.73
3,149.28
3,793.5
4,312.94
4,914
5,726.48
6,755.49
7,553.97
4,022.84
8,201.63
8,043.68
7,722.84
7,658.37
Book Value per Share
2,754.79
3,752.19
4,236.52
4,777.04
4,771.36
5,312.12
5,956.17
6,806.61
7,688.09
9,953.29
5,279.05
9,646.23
11,249.57
11,097.12
11,633.29
Tangible Book Value per Share
24
27
27
27
27
27
27
27
27
27
55
27
28
28
28
Basic Weighted Avg Shares
66,549
82,863
95,608
101,921
132,468
156,964
172,997
189,844
203,708
232,935
264,837
265,120
291,138
315,445
314,305
Sales/Revenue/Turnover
11.93
22.39
18.96
19.05
19.4
14.5
15.84
15.89
14.95
14.95
7.48
4.12
0.91
2.5
1.78
Operating Margin (%)
5,251
6,289
6,919
7,585
5,830
7,253
7,550
10,016
10,918
10,894
12,054
13,566
15,918
17,194
17,507
Depreciation Expense
8,745
18,642
14,466
14,716
17,561
15,730
22,619
23,426
26,839
25,451
16,138
3,709
-1,794
-5,149
-5,795
Net Income, GAAP
14.91
16.94
15.78
23.67
22.56
22.24
15.07
21.42
21.89
18.18
16.95
44.49
218.17
- -
177.94
Effective Tax Rate (%)
13.14
22.5
15.13
14.44
13.26
10.02
13.07
12.34
13.18
10.93
6.09
1.4
-0.62
-1.63
-1.84
Profit Margin (%)
24,056
47,590
63,351
59,297
62,702
69,999
82,551
87,191
128,317
169,263
142,624
78,466
163,494
91,469
111,790
Working Capital
9,003
21,420
27,935
25,319
23,007
37,876
34,420
20,599
44,608
95,239
66,061
48,656
113,850
62,717
71,331
LT Debt
68,437
104,319
118,808
132,222
152,231
165,152
183,267
201,091
223,126
284,740
304,756
303,495
342,981
338,321
356,487
Total Equity
- -
14.43
10.95
9.54
11.32
8.91
10.75
10.15
9.17
8.55
4.12
1.42
-0.65
- -
- -
Return on Invested Capital (%)
- -
28.38
16.85
14.51
14.2
11.34
14.14
13.37
12.58
9.44
5.4
1.56
-2.43
- -
4.26
Return on Capital (%)
- -
39.36
22.92
18.87
18.47
14.14
17.88
16.14
15.81
13.08
7.57
1.66
-0.8
-2.37
-2.67
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
99,654
111,081
99,234
LT Borrowings
72,315
61,518
70,235
LT Finance Leases
1,384
1,200
1,095
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
- -
Market Capitalization
538,030
439,377
523,654

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
254,039
258,382
264,267
Cash, Cash Equivalents & STI
92,128
98,187
99,021
Accounts Receivable, Net
67,079
67,323
67,884
Inventories
76,516
74,480
80,547
Total Current Liabilities
149,308
166,913
152,477
Payables & Accruals
- -
- -
- -
ST Debt
99,654
111,081
99,234
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
9.18%
-1.36%
Free Cash Flow
-111.18%
-104.5%
-213.01%
Net Income, GAAP
-0.93%
-16.03%
187%
Sales/Revenue/Turnover
12.2%
9.26%
8.35%
Total Cash Common Dividend
- -
4.11%
0.47%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68,404
69,900
71,519
81,314
291,138
2025
76,269
76,789
78,727
83,659
315,445
2026
75,130
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-10
-0.1
31
- -
-65
2025
94
31.45
-14.34
- -
-187
2026
70
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.67
2025
- -
- -
- -
- -
100.38
2026
- -
- -
- -
- -
- -
Similar Companies
ENvue Medical, Inc. (FEED)
QTREX Quantum Ltd. Warrant (QTEXW)
DRTECH Corporation (214680.KQ)
LabGenomics Co., Ltd. (084650.KQ)
WON TECH Co.,Ltd. (336570.KQ)
Aidite Qinhuangdao Technology Co Ltd (301580.SZ)
Business
i-SENS, Inc. (099190.KQ) develops, manufactures and markets in vitro diagnostic devices focused on blood glucose management and point-of-care testing; its core products include the CareSens series of blood glucose monitoring systems such as CareSens N, CareSens N Voice, CareSens N Premier, CareSens N Eco, CareSens PRO, CareSens H Beat, NoCoding1 Plus, KetoSens and CareSens S Fit; continuous glucose monitoring systems including CareSens Air and its upgraded version, CareSens Air Receiver, Sens365 data sharing platform and CareSens Air app; point-of-care systems comprising electrolyte analyzers like i-Smart 30 and i-Smart 300 blood gas analyzer, HbA1c analyzer A1Care, immunoassay analyzer ivisen IA-1100 and coagulation care devices; as well as veterinary care systems and diabetes management software SmartLog. The company, founded in 2000 and headquartered in Seoul, South Korea, operates manufacturing facilities in Korea and China with an annual production capacity of 2.1 billion blood glucose test strips; it maintains subsidiaries and offices including i-SENS USA Inc., i-SENS GmbH in Germany, i-SENS (Jiangsu) Co. Ltd. in China, i-SENS Biosensors India Pvt. Ltd., i-SENS Mexico S.A. de C.V., i-SENS Chile SpA and i-SENS Malaysia Sdn. Bhd., serving over 110 countries across North America, Europe, Asia and Latin America. Recent developments include the September 2023 launch of CareSens Air, Korea's first domestically developed continuous glucose monitoring system with CE certification, followed by its European market entry in 2024 and global expansion to over 30 countries by end-2025 with the November 2025 launch of CareSens Air Receiver to enhance insurance and tender access; completion of the Songdo second factory in October 2023; acquisition of AgaMatrix Inc. in July 2023 and CoaguSense Inc. in November 2016; as well as multiple awards in 2024 such as the Minister of Health and Welfare Commendation and consecutive Brand of the Year recognitions for CareSens.